155 related articles for article (PubMed ID: 8438466)
1. Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression.
Chong AS; Gebel H; Finnegan A; Petraitis EE; Jiang XL; Sankary HN; Foster P; Williams JW
Transplant Proc; 1993 Feb; 25(1 Pt 1):747-9. PubMed ID: 8438466
[No Abstract] [Full Text] [Related]
2. Modes of action of FK506, cyclosporin A, and rapamycin.
Morris R
Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
[No Abstract] [Full Text] [Related]
3. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection.
Wennberg L; Wallgren AC; Sundberg B; Rafael E; Zhu S; Liu J; Tibell A; Karlsson-Parra A; Groth CG; Korsgren O
Transplant Proc; 1995 Dec; 27(6):3314-5. PubMed ID: 8539967
[No Abstract] [Full Text] [Related]
4. Rapamycin effects on immunologic reconstitution.
Vogelsang GB; Hess AD
Transplant Proc; 1993 Feb; 25(1 Pt 1):727-8. PubMed ID: 8438459
[No Abstract] [Full Text] [Related]
5. Effect of rapamycin on the in vitro release of soluble interleukin-2 receptor by phytohemagglutinin, phorbol myristate acetate, and ionomycin-activated peripheral blood mononuclear cells.
Barkis I; Hadjiyannaki-Koniavitou K; Vareltzides A; Hornung N; Raskova J; Degiannis D
Transplant Proc; 1995 Feb; 27(1):432-4. PubMed ID: 7879050
[No Abstract] [Full Text] [Related]
6. Immunosuppressive agents: recent developments in molecular action and clinical application.
Gerber DA; Bonham CA; Thomson AW
Transplant Proc; 1998 Jun; 30(4):1573-9. PubMed ID: 9636637
[No Abstract] [Full Text] [Related]
7. In vivo mechanism of action of leflunomide: selective inhibition of the capacity of B lymphocytes to make T-independent xenoantibodies.
Lin Y; Waer M
Transplant Proc; 1996 Dec; 28(6):3085. PubMed ID: 8962194
[No Abstract] [Full Text] [Related]
8. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.
Zeevi A; Woan M; Yao GZ; Venkataramanan R; Todo S; Starzl TE; Duquesnoy RJ
Transplant Proc; 1991 Dec; 23(6):2928-30. PubMed ID: 1721315
[No Abstract] [Full Text] [Related]
10. FK 506 and rapamycin: molecular probes of T-lymphocyte activation.
Bierer BE; Jin YJ; Fruman DA; Calvo V; Burakoff SJ
Transplant Proc; 1991 Dec; 23(6):2850-5. PubMed ID: 1721296
[No Abstract] [Full Text] [Related]
11. Mechanism of action of rapamycin (Sirolimus, Rapamune).
Molnar-Kimber KL
Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
[No Abstract] [Full Text] [Related]
12. Rapamycin and cyclosporine produce synergistic but nonidentical mechanisms of immunosuppression.
Kimball PM; Kerman RH; Kahan BD
Transplant Proc; 1991 Feb; 23(1 Pt 2):1027-8. PubMed ID: 1989147
[No Abstract] [Full Text] [Related]
13. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
Lin Y; Waer M
Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
[No Abstract] [Full Text] [Related]
14. In vitro expression of activation markers and lymphocyte proliferation in response to interleukin 12: effect of immunosuppressive agents.
Degiannis D; Koniavitou K
Transplant Proc; 1996 Dec; 28(6):3062-4. PubMed ID: 8962187
[No Abstract] [Full Text] [Related]
15. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.
Böhler T; Waiser J; Budde K; Lichter S; Jauho A; Fritsche L; Korn A; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):2195-7. PubMed ID: 9723438
[No Abstract] [Full Text] [Related]
16. Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays.
Ferron GM; Jusko WJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):191-200. PubMed ID: 9655860
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect.
Cooper MH; Gregory SH; Thomson AW; Fung JJ; Starzl TE; Wing EJ
Transplant Proc; 1991 Dec; 23(6):2957-8. PubMed ID: 1721326
[No Abstract] [Full Text] [Related]
18. Effects of brequinar sodium on cynomolgus monkeys: immunosuppression and pharmacokinetics.
Jaffee BD; Jones EA; Zajac I; Magolda RL; Cramer DV; Makowka L
Transplant Proc; 1993 Feb; 25(1 Pt 1):710-1. PubMed ID: 8438449
[No Abstract] [Full Text] [Related]
19. The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506.
Nakajima H; Oka T
Transplant Proc; 1996 Apr; 28(2):1052-5. PubMed ID: 8623224
[No Abstract] [Full Text] [Related]
20. The actions of cyclosporin A and FK506 on T-lymphocyte activation.
Mattila PS
Biochem Soc Trans; 1996 Feb; 24(1):45-9. PubMed ID: 8674715
[No Abstract] [Full Text] [Related]
[Next] [New Search]
